BACKGROUND: The clinicopathological features and genomic rearrangements of anaplastic lymphoma kinase (ALK) fusion cases have not been fully identified. OBJECTIVE: Our objective was to explore the status of ALK in non-small-cell lung cancer (NSCLC) specimens, to explore the relationships between ALK status and clinicopathological features and to identify genomic rearrangements via capture-based next-generation sequencing (NGS). METHODS: We tested 9889 NSCLC specimens for ALK status using the Ventana anti-ALK (D5F3) antibody. Clinicopathological features were analyzed and genomic rearrangements identified using capture-based NGS in 76 ALK-positive cases. RESULTS: In total, 485 specimens (4.90%) tested positive for ALK. The positivity rate was higher for adenocarcinoma samples than for non-adenocarcinoma samples (6.03 vs. 1.47%; p < 0.001) and for biopsies/cell blocks than for surgical specimens (7.00 vs. 4.16%; p < 0.001). Patient age, patient sex, specimen type, specimen histotype, and patient smoking history were all significantly correlated with ALK status. Genomic rearrangements were detected in 98.68% (75/76) of the ALK-positive samples; 89.33% (67/75) carried the canonical EML4-ALK, and the remaining samples carried only noncanonical ALK rearrangements. Four of these noncanonical ALK fusion samples were identified as carrying EML4-ALK transcripts at the RNA level. A novel fusion variant, SRD5A2-ALK, was revealed. CONCLUSIONS: Younger patients with NSCLC, especially those aged < 30 years, were more likely to test positive for ALK. Positive ALK test results were more common in patients with invasive mucinous adenocarcinoma and solid-predominant invasive adenocarcinoma than in patients with other histotypes. Samples that carried only noncanonical ALK rearrangements may also have carried the canonical EML4-ALK, which was not detected by capture-based NGS. EML4-ALK transcripts might result from rare splicing mechanisms without genomic rearrangements.
BACKGROUND: The clinicopathological features and genomic rearrangements of anaplastic lymphoma kinase (ALK) fusion cases have not been fully identified. OBJECTIVE: Our objective was to explore the status of ALK in non-small-cell lung cancer (NSCLC) specimens, to explore the relationships between ALK status and clinicopathological features and to identify genomic rearrangements via capture-based next-generation sequencing (NGS). METHODS: We tested 9889 NSCLC specimens for ALK status using the Ventana anti-ALK (D5F3) antibody. Clinicopathological features were analyzed and genomic rearrangements identified using capture-based NGS in 76 ALK-positive cases. RESULTS: In total, 485 specimens (4.90%) tested positive for ALK. The positivity rate was higher for adenocarcinoma samples than for non-adenocarcinoma samples (6.03 vs. 1.47%; p < 0.001) and for biopsies/cell blocks than for surgical specimens (7.00 vs. 4.16%; p < 0.001). Patient age, patient sex, specimen type, specimen histotype, and patient smoking history were all significantly correlated with ALK status. Genomic rearrangements were detected in 98.68% (75/76) of the ALK-positive samples; 89.33% (67/75) carried the canonical EML4-ALK, and the remaining samples carried only noncanonical ALK rearrangements. Four of these noncanonical ALK fusion samples were identified as carrying EML4-ALK transcripts at the RNA level. A novel fusion variant, SRD5A2-ALK, was revealed. CONCLUSIONS: Younger patients with NSCLC, especially those aged < 30 years, were more likely to test positive for ALK. Positive ALK test results were more common in patients with invasive mucinous adenocarcinoma and solid-predominant invasive adenocarcinoma than in patients with other histotypes. Samples that carried only noncanonical ALK rearrangements may also have carried the canonical EML4-ALK, which was not detected by capture-based NGS. EML4-ALK transcripts might result from rare splicing mechanisms without genomic rearrangements.
Authors: Maximilian von Laffert; Arne Warth; Roland Penzel; Peter Schirmacher; Keith M Kerr; Göran Elmberger; Hans-Ulrich Schildhaus; Reinhard Büttner; Fernando Lopez-Rios; Simone Reu; Thomas Kirchner; Patrick Pauwels; Katja Specht; Enken Drecoll; Heinz Höfler; Daniela Aust; Gustavo Baretton; Lukas Bubendorf; Sonja Stallmann; Annette Fisseler-Eckhoff; Alex Soltermann; Verena Tischler; Holger Moch; Frederique Penault-Llorca; Hendrik Hager; Frank Schäper; Dido Lenze; Michael Hummel; Manfred Dietel Journal: J Thorac Oncol Date: 2014-11 Impact factor: 15.609
Authors: Jason N Rosenbaum; Ryan Bloom; Jason T Forys; Jeff Hiken; Jon R Armstrong; Julie Branson; Samantha McNulty; Priya D Velu; Kymberlie Pepin; Haley Abel; Catherine E Cottrell; John D Pfeifer; Shashikant Kulkarni; Ramaswamy Govindan; Eric Q Konnick; Christina M Lockwood; Eric J Duncavage Journal: Mod Pathol Date: 2018-01-12 Impact factor: 7.842
Authors: Marta Salido; Lara Pijuan; Luz Martínez-Avilés; Ana B Galván; Israel Cañadas; Ana Rovira; Montserrat Zanui; Alejandro Martínez; Raquel Longarón; Francisco Sole; Sergio Serrano; Beatriz Bellosillo; Murry W Wynes; Joan Albanell; Fred R Hirsch; Edurne Arriola Journal: J Thorac Oncol Date: 2011-01 Impact factor: 15.609
Authors: Murry W Wynes; Lynette M Sholl; Manfred Dietel; Ed Schuuring; Ming S Tsao; Yasushi Yatabe; Raymond R Tubbs; Fred R Hirsch Journal: J Thorac Oncol Date: 2014-05 Impact factor: 15.609
Authors: Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb Journal: Cell Date: 2007-12-14 Impact factor: 41.582
Authors: K Takeuchi; Y Togashi; Y Kamihara; T Fukuyama; H Yoshioka; A Inoue; H Katsuki; K Kiura; K Nakagawa; T Seto; M Maemondo; T Hida; M Harada; Y Ohe; N Nogami; N Yamamoto; M Nishio; T Tamura Journal: Ann Oncol Date: 2015-10-20 Impact factor: 32.976
Authors: Yan Li; Yan Tan; Song Hu; Jun Xie; Zhantao Yan; Xian Zhang; Yun Zong; Han Han-Zhang; Qing Li; Chong Li Journal: J Cancer Date: 2021-04-02 Impact factor: 4.207
Authors: Alexa B Schrock; Russell Madison; Mark Rosenzweig; Justin M Allen; Rachel L Erlich; Siao-Yi Wang; Tarek Chidiac; Vodur Suresh Reddy; Jonathan W Riess; Ahmet Ersin Yassa; Abdur Shakir; Vincent A Miller; Brian M Alexander; Jeffrey Venstrom; Kimberly McGregor; Siraj M Ali Journal: Lung Cancer (Auckl) Date: 2020-04-17